BRNS
Barinthus Biotherapeutics plc.
$0.7200
+10.43%
$29.6M
No data for this timeframe.
Vol
Market Cap$29.6M
Cap SizeNano Cap
Inst. Holders2 funds
Inst. Value$102.6K
Inst. Activity1 buys / 1 sells
SEC Reports1
Press Releases1
Recent Activity
May 1, 2026
SEC
Douglas J. Swirsky filed a Form 3 initial statement of beneficial ownership as the new Principal Accounting Officer of B
3 — Impact 2/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
143,100 shares ($100.2K)
Inst.
MORGAN STANLEY — TRIM
3,406 shares ($2.4K)
May 5, 2026
earnings_calendar
BRNS Q1 2026 Earnings Before Market Open — 2026-05-05
Mar 13, 2026
Press
Barinthus Biotherapeutics reported its 2025 financial results, highlighting a net loss of $66.4 million and a significan
Impact 7/10
Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$5.50 (Nov 2025)
Current $0.7240
Low $4.00
Median $5.50
High $7.00
2 analysts
$4.00
$7.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 17, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 21, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jan 13, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Nov 19, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Nov 8, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.28 ▲ +15.2% | $-0.28 — $-0.28 | 46% YoY | 1 |
| Next Q | $-0.29 ▲ +13.4% | $-0.29 — $-0.29 | -19% YoY | 1 |
| Current FY | $-1.15 ▲ +13.9% | $-1.15 — $-1.15 | 25% YoY | 1 |
| Next FY | $-1.15 | $-1.15 — $-1.15 | 0% YoY | 1 |
Latest Reports
NEUTRAL
3
2/10
Douglas J. Swirsky filed a Form 3 initial statement of beneficial ownership as the new Principal Accounting Officer of B
May 1, 2026
BEARISH
Press
7/10
Barinthus Biotherapeutics reported its 2025 financial results, highlighting a net loss of $66.4 million and a significan
Mar 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $100.2K | DOUBLED |
| MORGAN STANLEY | $2.4K | TRIM |
2 institutional holders with $102.6K total value (146,506 shares) as of 2025-Q4. Top holders: RENAISSANCE, MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 143,100 | $100.2K | 97.7% | DOUBLED +115.8% |
| 2 | MORGAN STANLEY | 3,406 | $2.4K | 2.3% | TRIM -31.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 66,300 | 143,100 | +115.8% | $100.2K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 4,942 | 3,406 | -31.1% | $2.4K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 36,300 | 66,300 | +82.6% | $82.9K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 871 | 4,852 | +457.1% | $4.5K | 2025-Q2 |
| CITADEL ADVISORS LLC | NEW | — | 26,172 | — | $25.9K | 2025-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 8,021 | 871 | -89.1% | $847.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 27,900 | 35,100 | +25.8% | $42.4K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 11,983 | 8,021 | -33.1% | $9.7K | 2024-Q4 |
| CITADEL ADVISORS LLC | EXIT | 27,717 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | ADD | 8,873 | 11,983 | +35.1% | $14.3K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 2.0/10.
Historical analyst distribution (last covering-analyst action Nov 2025): 88% buy across 8 analysts — 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$5.50 mean target (Nov 2025)
$4.00 Low
$7.00 High
| Metric | Value |
|---|---|
| Current Price | $0.7240 |
| Target Low | $4.00 |
| Target Mean | $5.50 |
| Target Median | $5.50 |
| Target High | $7.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.28 | $-0.28 | $-0.28 | 46.2% | +15.2% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.29 | $-0.29 | $-0.29 | -18.9% | +13.4% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-1.15 | $-1.15 | $-1.15 | 24.6% | +13.9% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-1.15 | $-1.15 | $-1.15 | 0.0% | +0.0% | 1↑ 0↓ | $0.0B | — | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.280 | |
| 7d ago | $-0.330 | +0.050 |
| 30d ago | $-0.330 | +0.050 |
| 60d ago | $-0.330 | +0.050 |
| 90d ago | $-0.330 | +0.050 |
6 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 5 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 17, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 21, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 13, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 19, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Oct 1, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Sep 26, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 13, 2024 | Alliance Global Partners | MAINTAIN | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 13, 2024 | Barclays | MAINTAIN | — | Overweight |
| Jun 7, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 22, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 19, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 21, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 28, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Sep 25, 2023 | Alliance Global Partners | INITIATE | — | Buy |
| Sep 25, 2023 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
| Aug 18, 2023 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Jun 13, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 16, 2023 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Mar 29, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Mar 27, 2023 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Mar 21, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Aug 15, 2022 | Morgan Stanley | MAINTAIN | — | Overweight |
| Aug 11, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| May 17, 2022 | Morgan Stanley | MAINTAIN | — | Overweight |
| May 13, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Dec 15, 2021 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| May 25, 2021 | William Blair | INITIATE | — | Outperform |
| May 25, 2021 | Jefferies | INITIATE | — | Buy |
| May 25, 2021 | Morgan Stanley | INITIATE | — | Overweight |
| May 24, 2021 | HC Wainwright & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 5, 2026
earnings_calendar
BRNS Q1 2026 Earnings Before Market Open — 2026-05-05
Apr 30, 2026
Clinical Trial
Efficacy of VTP-300 in Chronic Hepatitis B Infection
Phase Phase 2 — COMPLETED
Apr 30, 2026
earnings
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
<p align="left">GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”)
Mar 18, 2026
earnings_calendar
BRNS Q4 2025 Earnings After Market Close — 2026-03-18
Mar 13, 2026
earnings
Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments
<p align="left">GERMANTOWN, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”)